Hassman Research Institute
Berlin, New Jersey, 08009, United States
NCT Number: NCT04060654
A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Berlin, New Jersey, 08009, United States
This study is being conducted to assess the longer-term safety of an abbreviated initiation protocol of SUBLOCADE in subjects who have completed the INDV-6000-403 study. It is also to provide treatment to these individuals while they seek longer-term treatment arrangements, as on average it can take an individual with opioid use disorder (OUD) 6 months between seeking treatment and achieving an appointment at a provider in the United States (US).
Subjects who have completed the end of treatment (EOT) procedures for the INDV-6000-403 study may be eligible for participation. It is planned that the EOT visit for INDV-6000-403, which will occur approximately 28 days after the subject's first dose of SUBLOCADE, and Day 1 for INDV-6000-404 will occur within 2 days of the EOT visit, and that EOT assessments will serve as the screening assessments for this study.
On Day 1, eligible subjects will receive a subcutaneous (SC) injection of 300 mg SUBLOCADE. Subjects will return to the clinic for subsequent injections approximately every 4 weeks for a total of up to 5 injections. Adverse events and concomitant medications will be captured throughout the study, female subjects of childbearing potential will receive urine pregnancy tests and all subjects will have urine drug screening (UDS) and evaluation of the previous injection site performed. Subjects will otherwise be treated in accordance with local standard of care, and SUBLOCADE doses will be based on the medical judgment of the Investigator.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SUBLOCADE to be administered approximately every 4 weeks per local standard of care
Other names: Extended release buprenorphine
Time frame: From time of informed consent at Day 1 until EOT, assessed up until Day 141
Study will report the number of participants with the occurrence of any TEAE during the treatment period.
Indivior Inc.
Industry
An Open-label, Treatment Extension Study for the Rapid Initiation of Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE™)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04345718
Chemically-Induced Disorders, Hemic and Lymphatic Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT04982627
Behavior, Chemically-Induced Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT06651177
Chemically-Induced Disorders, Hemic and Lymphatic Diseases
Jacksonville, Florida, United States
View Trial DetailsNCT07451197
Chemically-Induced Disorders, Hemic and Lymphatic Diseases
Chicago, Illinois, United States
View Trial Details